herpes zoster
Vaccines · 2007–2023
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| varicella zoster virus recombinant vaccine Prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN) for non-Indigenous individuals aged 65 to 69 years and ≥71 years. | Jul 2023 | Recommended with restriction | input received Gastroenterological Society of Australia · Colitis Australia · Pain Australia |
| varicella zoster virus recombinant vaccine Prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN) in non-Indigenous people ≥65 years of age and Aboriginal and Torres Strait Islander people… | Mar 2023 | Recommended with restriction | 9 individuals Myeloma Australia · Immunisation Foundation · Pain Australia · Controlled Health Organisation · Australian Rheumatology Association · Multiple Sclerosis Australia · Australian Society of Clinical Immunology and Allergy · Pharmaceutical Society · National Aboriginal Community Controlled Health Organisation |
| varicella zoster virus recombinant vaccine Prevention of herpes zoster in non-Indigenous individuals aged 65 years and older, Aboriginal and Torres Strait Islander individuals aged 50 years and older,… | Nov 2023 | Recommended | input received Australian Rheumatology Association · Colitis Australia · Lung Foundation Australia · Immunisation Coalition · Kidney Health Australia · MS Australia · Australian Society of Clinical Immunology and Allergy |
| recombinant varicella zoster virus glycoprotein E antigen (AS01B adjuvanted) vaccine Prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN) in adults aged 60 years and older, with a five-year catch-up program. | Nov 2018 | Not recommended | none received |
| zoster virus vaccine live Prevention of herpes zoster (shingles) and post-herpetic neuralgia (PHN) in older adults aged 70 years and a catch-up cohort of 71-79 year olds. | Mar 2014 | Not recommended | unclear |
| zoster virus vaccine live Prevention of herpes zoster and post-herpetic neuralgia (PHN) in immunocompetent persons aged 70 years, and a catch-up cohort of immunocompetent persons aged… | Nov 2014 | Recommended | 4 individuals |
| zoster virus vaccine live (Oka/Merk) Prevention of herpes zoster (shingles), prevention of postherpetic neuralgia, and reduction of acute and chronic zoster-associated pain in immunocompetent… | Mar 2008 | Recommended with restriction | no section in document |
| zoster virus vaccine live (Oka/Merck) Prevention of herpes zoster (shingles) and postherpetic neuralgia (PHN) in immunocompetent persons aged 60 years and over, with an ongoing cohort of… | Nov 2007 | Deferred | no section in document |
Who spoke
Australian Rheumatology Association · Colitis Australia · Australian Society of Clinical Immunology and Allergy · Pain Australia · Lung Foundation Australia · Immunisation Coalition · Kidney Health Australia · MS Australia · Gastroenterological Society of Australia · Myeloma Australia · Immunisation Foundation · Controlled Health Organisation
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| valaciclovirAPO-VALACICLOVIR valaciclovir hydrochloride monohydrate 1000mg tablet | 2000 | 56 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 4 of 6 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.